Overview Dividends

(LRCX) Lam Research - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5128073062

Deposition,Etch,Clean,Refurbish,Service

LRCX EPS (Earnings per Share)

EPS Growth (3Y CAGR): -54.08%
EPS Trend (3Y Correlation): -82.5%

LRCX Revenue

Revenue Growth (3Y CAGR): 0.32%
Revenue Trend (3Y Correlation): 51.6%

Risk via 10d forecast
Volatility	51.7%
Value at Risk 5%th	76.0%
Relative Tail Risk	-5.40%

Reward TTM
Sharpe Ratio	1.62
Alpha	75.72

Character TTM
Hurst Exponent	0.451
Beta	1.849
Beta Downside	1.792

Drawdowns 3y
Max DD	47.10%
Mean DD	13.03%
Median DD	8.33%

Description: LRCX Lam Research September 24, 2025

Lam Research Corp (NASDAQ:LRCX) designs, manufactures, markets, refurbishes, and services a full suite of semiconductor processing tools used to build integrated circuits worldwide. Its portfolio spans deposition (ALTUS, SABRE, SPEED, Striker, VECTOR), etch (Flex, Vantex, Kiyo, Syndion, Versys), cleaning (Coronus, Da Vinci, DV-Prime, EOS, SP series) and advanced platform solutions (Reliant, Sense.i), supported by service, spares, and upgrades.

Key quantitative signals (FY 2023): revenue of $17.6 billion, up ~13 % YoY, driven by strong demand for advanced-node equipment (3 nm and below) and growth in AI-related workloads. The company’s gross margin held at ~46 %, reflecting pricing power in a concentrated market where Lam commands ~30 % share of the global wafer-fab equipment spend. Capital-expenditure cycles in the semiconductor sector, amplified by the U.S. CHIPS Act and rising fab capacity in Taiwan, South Korea, and the U.S., remain the primary macro driver of Lam’s order backlog.

For a deeper, data-rich evaluation of Lam’s valuation dynamics, you may find ValueRay’s analyst toolkit useful for extending this initial overview.

LRCX Stock Overview

Market Cap in USD	200,148m
Sub-Industry	Semiconductor Materials & Equipment
IPO / Inception	1984-05-11
Return 12m vs S&P 500	74.8%
Analyst Rating	4.33 of 5

LRCX Dividends

Dividend Yield	0.64%
Yield on Cost 5y	2.29%
Yield CAGR 5y	15.10%
Payout Consistency	100.0%
Payout Ratio	21.6%

LRCX Growth Ratios

CAGR 3y	50.29%
CAGR/Max DD Calmar Ratio	1.07
CAGR/Mean DD Pain Ratio	3.86
Current Volume	15076.1k
Average Volume	10440.6k

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (5.81b TTM) > 0 and > 6% of Revenue (6% = 1.18b TTM)

FCFTA 0.27 (>2.0%) and ΔFCFTA 1.93pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 41.34% (prev 52.27%; Δ -10.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.29 (>3.0%) and CFO 6.38b > Net Income 5.81b (YES >=105%, WARN >=100%)

Net Debt (-2.21b) to EBITDA (7.01b) ratio: -0.32 <= 3.0 (WARN <= 3.5)

Current Ratio 2.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (1.27b) change vs 12m ago -2.66% (target <= -2.0% for YES)

Gross Margin 49.31% (prev 47.47%; Δ 1.85pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 94.57% (prev 79.82%; Δ 14.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 49.37 (EBITDA TTM 7.01b / Interest Expense TTM 134.0m) >= 6 (WARN >= 3)

Altman Z'' 11.78

(A) 0.37 = (Total Current Assets 14.81b - Total Current Liabilities 6.71b) / Total Assets 21.90b

(B) 1.38 = Retained Earnings (Balance) 30.23b / Total Assets 21.90b

warn (B) unusual magnitude: 1.38 — check mapping/units

(D) 2.58 = Book Value of Equity 30.16b / Total Liabilities 11.71b

Total Rating: 11.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 82.59

1. Piotroski 9.0pt = 4.0

2. FCF Yield 2.95% = 1.48

3. FCF Margin 29.85% = 7.46

4. Debt/Equity 0.44 = 2.41

5. Debt/Ebitda -0.32 = 2.50

6. ROIC - WACC (= 27.20)% = 12.50

7. RoE 60.57% = 2.50

8. Rev. Trend 51.62% = 3.87

9. EPS Trend -82.52% = -4.13

What is the price of LRCX shares?

As of November 15, 2025, the stock is trading at USD 148.26 with a total of 15,076,125 shares traded.
Over the past week, the price has changed by -6.96%, over one month by +7.19%, over three months by +38.34% and over the past year by +100.34%.

Is Lam Research a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Lam Research (NASDAQ:LRCX) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 82.59 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LRCX is around 178.64 USD . This means that LRCX is currently undervalued and has a potential upside of +20.49% (Margin of Safety).

Is LRCX a buy, sell or hold?

Lam Research has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy LRCX.

Strong Buy: 20
Buy: 4
Hold: 9
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the LRCX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	158	6.6%
Analysts Target Price	158	6.6%
ValueRay Target Price	206.4	39.2%

LRCX Fundamental Data Overview November 09, 2025

Market Cap USD = 200.15b (200.15b USD * 1.0 USD.USD)
P/E Trailing = 35.1766
P/E Forward = 32.8947
P/S = 10.2159
P/B = 18.796
P/EG = 2.3915
Beta = 1.779
Revenue TTM = 19.59b USD
EBIT TTM = 6.61b USD
EBITDA TTM = 7.01b USD
Long Term Debt = 3.72b USD (from longTermDebt, last fiscal year)
Short Term Debt = 754.4m USD (from shortTermDebt, last quarter)
Debt = 4.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.21b USD (from netDebt column, last quarter)
Enterprise Value = 197.94b USD (200.15b + Debt 4.48b - CCE 6.69b)
Interest Coverage Ratio = 49.37 (Ebit TTM 6.61b / Interest Expense TTM 134.0m)
FCF Yield = 2.95% (FCF TTM 5.85b / Enterprise Value 197.94b)
FCF Margin = 29.85% (FCF TTM 5.85b / Revenue TTM 19.59b)
Net Margin = 29.66% (Net Income TTM 5.81b / Revenue TTM 19.59b)
Gross Margin = 49.31% ((Revenue TTM 19.59b - Cost of Revenue TTM 9.93b) / Revenue TTM)
Gross Margin QoQ = 50.43% (prev 50.08%)
Tobins Q-Ratio = 9.04 (Enterprise Value 197.94b / Total Assets 21.90b)
Interest Expense / Debt = 0.02% (Interest Expense 695.0k / Debt 4.48b)
Taxrate = 15.63% (290.5m / 1.86b)
NOPAT = 5.58b (EBIT 6.61b * (1 - 15.63%))
Current Ratio = 2.21 (Total Current Assets 14.81b / Total Current Liabilities 6.71b)
Debt / Equity = 0.44 (Debt 4.48b / totalStockholderEquity, last quarter 10.19b)
Debt / EBITDA = -0.32 (Net Debt -2.21b / EBITDA 7.01b)
Debt / FCF = -0.38 (Net Debt -2.21b / FCF TTM 5.85b)
Total Stockholder Equity = 9.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 26.53% (Net Income 5.81b / Total Assets 21.90b)
RoE = 60.57% (Net Income TTM 5.81b / Total Stockholder Equity 9.59b)
RoCE = 49.68% (EBIT 6.61b / Capital Employed (Equity 9.59b + L.T.Debt 3.72b))
RoIC = 39.75% (NOPAT 5.58b / Invested Capital 14.04b)
WACC = 12.55% (E(200.15b)/V(204.63b) * Re(12.83%) + D(4.48b)/V(204.63b) * Rd(0.02%) * (1-Tc(0.16)))
Discount Rate = 12.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.02%
[DCF Debug] Terminal Value 64.92% ; FCFE base≈5.45b ; Y1≈6.05b ; Y5≈7.93b
Fair Price DCF = 55.70 (DCF Value 69.96b / Shares Outstanding 1.26b; 5y FCF grow 12.81% → 3.0% )
EPS Correlation: -82.52 | EPS CAGR: -54.08% | SUE: 0.18 | # QB: 0
Revenue Correlation: 51.62 | Revenue CAGR: 0.32% | SUE: 2.36 | # QB: 5

Additional Sources for LRCX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle